Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415009 | 0.98 | MAPT (0.43) | MAPTPKMALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL6282864 | 0.91 | MAPT (0.42) | MAPTPKMALDH1A1KDM4EMEN1 | |
| Bromide SCHEMBL6281750 | 0.88 | MAPT (0.40) | MAPTPKMALDH1A1KDM4EMEN1 | |
| SCHEMBL16925388 | 0.84 | MAPT (0.45) | MAPTPKMALDH1A1KDM4EMEN1 | |
| SCHEMBL8242838 | 0.83 | MAPT (0.37) | MAPTPKMALDH1A1KDM4EMEN1 | |
| SCHEMBL6346612 | 0.81 | MAPT (0.45) | MAPTPKMALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL653032 | 0.81 | CHRNB2 (0.38) | KDM4EKMT2AHSD17B10 | |
| SCHEMBL19402623 | 0.81 | TLR4 (0.46) | MAPTPKMALDH1A1KDM4EMEN1 | |
| SCHEMBL7722190 | 0.80 | MAPT (0.38) | MAPTPKMALDH1A1KDM4EMEN1 | |
| SCHEMBL567797 | 0.80 | CHRNB2 (0.39) | KDM4EKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20230100186-A1 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-03-30 | — | — | US | disclosed |
| EP-3546463-B1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| CN-108136040-B | Multiligand agents for drug delivery | 阿克丘勒斯治疗公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111592479-B | Aloe-emodin nitrogen heterocyclic derivative and preparation method and application thereof | 四川大学华西医院 | 2021-10-19 | — | — | CN | disclosed |
| WO-2021146334-A1 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3170823-B1 | 6,7-DIHYDRO-2H-PYRAZOLO[4,3-C]PYRIDIN-3(5H)-ONE DERIVATIVES AND THEIR USE FOR TREATING A DISEASE ASSOCIATED WITH AMPK KINASE ACTIVITY | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-28 | — | — | EP | disclosed |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| CN-111592479-A | Aloe-emodin nitrogen heterocyclic derivative and preparation method and application thereof | 四川大学华西医院 | 2020-08-28 | — | — | CN | disclosed |
| CN-87107643-A | CONDENSED CYCLIC TRIAZOLE DERIVATIVES | — | 1988-08-24 | — | — | CN | disclosed |
| EP-0087280-B1 | 3-(2-MONO-AND DIALKYLAMINO)PROPYL(-1,2,3,4-TETRAHYDRO-5H-(1) BENZOPYRANO(3,4-C)PYRIDIN-5-ONES AND DERIVATIVES THEREOF, A PROCESS FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0087280-A2 | 3-(2-Mono-and dialkylamino)propyl(-1,2,3,4-tetrahydro-5H-(1) benzopyrano(3,4-c)pyridin-5-ones and derivatives thereof, a process for their production, and pharmaceutical compositions containing such compounds | WARNER-LAMBERT COMPANY (US) | 1983-08-31 | — | — | EP | disclosed |
| US-4382939-A | 3-[2-(Mono-and dialkylamino)propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-C]pyridin-5-ones useful for treating bronchospastic diseases | WARNER LAMBERT COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
| US-4276296-A | Substituted benzopyrano[3,4-c]pyridines, compositions and use thereof | WARNER-LAMBERT COMPANY (US) | 1981-06-30 | — | — | US | disclosed |
| US-4018766-A | BRONCHODILATORS | WARNER-LAMBERT COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4013671-A | Substituted benzopyrano[3,4-c]pyridines and process for their preparation | WARNER-LAMBERT COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3984546-A | Substituted benzopyrano [3,4-c]pyridines for the treatment of bronchial asthma | WARNER-LAMBERT COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3961057-A | Benzopyrano(3,4-C)pyridine bronchodilators | WARNER-LAMBERT COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
| US-3946008-A | Substituted benzopyrano[3,4-c]pyridines | WARNER-LAMBERT COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100186-A1 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | OPRL1, OPRK1, CYP2F1 | GAA 4045/4885MAPT 2786/4885PKM 3882/4885 |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | MTHFD1, MTHFD2, DHFR | GAA 1082/4885MAPT 1568/4885PKM 2989/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | GAA 1251/4885MAPT 2531/4885PKM 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.